NoeticInsight

12/03/2025

📈The ongoing phase 3 trial, RadComp, shows similar health-related quality of life for proton radiotherapy compared to photon radiotherapy. If the results remain consistent as the trial progresses over the next few years, proton therapy may potentially offer patients a treatment with minimal exposure to tissues beyond the tumor and may reduce radiation-associated morbidity.

⚕️To track developments in clinical trial results like RadComp, connect with NoeticInsight: https://hubs.li/Q03TVyKc0



Source: https://hubs.li/Q03TVG2J0

12/01/2025

💊Have you been staying on top of novel drug approvals this year? These products have been approved for various cancers and diseases such as moderate-to-severe acute pain, eczema, generalized myasthenia gravis, presbyopia, and more.

⭐For rapid access to data and insights, get started with NoeticInsight: https://hubs.li/Q03TVcMj0



Source: https://hubs.li/Q03TVtMy0

11/24/2025

💡The Cancer AI Alliance—made up of National Cancer Institute-designated cancer centers and technology industry leaders—have announced a new platform that uses anonymous individual data to train AI with the aim of eradicating cancer. The platform will enable researchers and clinicians to train AI models with clinical data from cancer centers so they can discover insights faster and more efficiently than ever before.

👉If you’d like to access data and insight now, learn how NoeticInsight can provide strategic solutions: https://hubs.li/Q03T3Clt0



Source: https://hubs.li/Q03T3x8M0

11/21/2025

🔍In the trial, patients receiving a combination therapy of osimertinib plus platinum-pemetrexed chemotherapy had a median overall survival of 47.5 months compared to 37.6 months in the osimertinib monotherapy group. The results mark an additional new treatment approach in NSCLC which will allow for better tailoring of treatments for patients.

📈 To deep dive on the meaning of these results, check out NoeticInsight: https://hubs.li/Q03T2X5G0



Read more: https://hubs.li/Q03T2Xg40

11/18/2025

⭐The STARS trial studied patients with early stage disease and is the first to report 10-year clinical outcomes comparing stereotactic radiation and surgical resection for operable NSCLC. The findings support stereotactic radiation as an alternative to surgery, offering patients a less-invasive option to treat their lung cancer.

👉Access data faster and more efficiently with NoeticInsight: https://hubs.li/Q03T2wzk0

Source: https://hubs.li/Q03T2vhY0

11/17/2025

👉As a PRIMO sponsor, you can support learning and development for oncology practitioners and help them understand how and when to integrate immuno and molecular therapies into their practices.

🔍PRIMO Summits are great opportunities to connect with top US-based practicing clinicians—the decision-makers and prescribers on the front-lines of patient care.
Contact us to get started: https://hubs.ly/Q03SVJSG0

11/03/2025

👉With its ability to analyze large data sources and use deep learning to gain insights, AI has the potential to drastically expedite drug discovery. Now, AI may even be able to discover disease biomarkers and analyze electronic health record (EHR) data to find potential candidates for clinical trials.

📌If you’re looking for a partner to help dig through clinical insights, reach out to us! https://hubs.li/Q03Rh_4L0

10/31/2025

👉In the MARIPOSA trial, 3-year overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC was 60% compared to 51% in the patient population receiving osimertinib.

📌Want to know how clinical trials will affect the market and prescribing patterns? Learn more about our services: https://hubs.li/Q03QR5jv0


Source: https://hubs.li/Q03QR5T40

10/29/2025

In a fast-moving market, staying ahead means being faster, smarter, and more connected.

That’s where NoeticInsight comes in. From rapid research to real-time testing, we help pharma teams make confident decisions backed by expert input and timely data.

Read to learn more? Let’s connect: https://hubs.li/Q03L9M2w0

10/28/2025

📌PRIMO creates a place for exchanging insights and key developments about the latest cancer innovations with attendees including faculty, US practicing clinicians, decision makers, and prescribers.

Contact us to learn more about PRIMO Summits! https://hubs.li/Q03N9kYw0

10/27/2025

🌍 The global healthcare market is expanding fast, with projections showing growth from $11.9T in 2022 to $15.8T by 2025. What’s fueling it? Innovation, shifting demographics, and rising chronic conditions.

As the landscape evolves, informed decisions matter more than ever. We help pharma teams stay ahead by connecting you with real-world expert perspectives and strategic market intelligence, so they can adapt, respond, and lead with clarity.

📖 Explore how research is shaping the future of healthcare: https://hubs.li/Q03L9JKQ0

Discover how healthcare market research empowers pharmaceutical marketers with insights and strategies for navigating an evolving industry landscape.

10/23/2025

📍 Real-time insights from the congress floor.

When your team is attending a congress like EAHAD, speed matters. NoeticInsight helps you capture expert feedback as the data is being presented, not weeks later. Pharma teams can engage HCPs and KOLs in the moment and develop actionable insights while conversations are still fresh. Whether you're refining your strategy or planning your next move, we help you stay ahead.

Learn more: https://hubs.li/Q03L9CWy0